Moderna Q4 revenue falls to $1.0 billion; net loss of $1.1 billion
Moderna reported fourth-quarter 2024 revenue of $1.0 billion, down from $2.8 billion a year earlier, and a net loss of $1.1 billion, compared with net income of $217 million in the same quarter of 2023. For the full year, revenue fell to $3.2 billion from $6.8 billion, but the net loss narrowed to $3.6 billion from $4.7 billion, and the company reiterated its 2025 revenue range of $1.5 to $2.5 billion.
Key points
- Q4 2024 net loss was $1.1 billion, or $(2.91) per share, versus Q4 2023 net income of $217 million
- Q4 2024 cost of sales included a non-cash charge of $238 million tied to termination of a contract manufacturing agreement
- Full-year 2024 revenue was $3.2 billion versus $6.8 billion in 2023; net loss was $3.6 billion versus $4.7 billion
- 2025 revenue expected at $1.5 to $2.5 billion (reiterated), with year-end 2025 cash and investments projected at approximately $6 billion
The filing
Written by AI on Nov 8, 2026, 1:21 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 14, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.